EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR ‐Mutant Non‐Small Cell Lung Cancer

Fen Wang, Xue-Wu Wei, Ming-Yi Yang, Chang Lu, Xiao-Rong Yang, Jia-Yi Deng, Zhi-Hong Chen, Qing Zhou iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Fen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzh…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, DNA Repair. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases- National Science and Technology Major Project, The National Natural Science Foundation of China, MOE Changjiang Distinguished Professor Supporting Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The epidermal growth factor receptor mutant (EGFRm) non‐small cell lung cancer (NSCLC) has a unique “cold” immune profile. DNA damage repair (DDR) genes are closely related to tumorigenesis and the effectiveness of immunotherapy in many tumors. However, the role and mechanism of DDR in the genesis and progression of EGFRm NSCLC remain unclear.

Methods

This study included 101 EGFRm NSCLC samples from The Cancer Genome Atlas (TCGA) dataset and a GSE31210 dataset (external set) from the GEO database. Cluster analysis was used to identify different subtypes of EGFRm NSCLC based on the expression of DDR genes. Univariate and LASSO regression analysis was used to develop a DDR‐based predictive model. The prognostic significance of this model was assessed using Cox regression, Kaplan–Meier, and receiver operating characteristic (ROC) curve analyses. Bioinformatics analysis was performed to investigate the clinicopathological characteristics and immune profiles associated with this model. In vitro experiment was performed to testify the role of DDR genes in EGFRm NSCLC.

Results

We identified two subtypes of EGFRm NSCLC: DDR‐activated and DDR‐suppressed. The DDR‐activated subtype showed more aggressive clinical behavior and poorer prognosis and was more responsive to immunotherapy. A prognostic model for EGFRm NSCLC was constructed using four DDR genes: CAPS , FAM83A , IGLV8‐61 , and SLC7A5 . The derived risk score could serve as an independent prognostic indicator. High‐ and low‐risk patients exhibited distinct clinicopathological characteristics, immune profiles, and responses to immunotherapy. The T‐cell inflammation and Tumor Immune Dysfunction and Exclusion (TIDE) scores differed between the high‐ and low‐risk subgroups, with both showing enhanced effectiveness of immunotherapy in the low‐risk subgroup. Targeted therapy such as BI.2536, an inhibitor of polo‐like kinase 1, could be effective for patients with high‐risk EGFRm NSCLC. Meanwhile, in vitro detection approved the role of DDR genes in EGFRm NSCLC response.

Conclusion

This study demonstrated a diversity of DDR genes in EGFRm NSCLC and developed a predictive model using these genes. This model could assist in identifying potential candidates for immunotherapy and in assessing personalized treatment and prognosis of patients with EGFRm NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyDNA RepairMutationBiomarkers, TumorHumansPrognosisFemaleMaleErbB ReceptorsMiddle Aged

Stichwörter der Autor:innen

DNA‐damage repairepidermal growth factor receptornon‐small cell lung cancerprognostic model

Substanzen

ErbB ReceptorsEGFR protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

ORCID-Profile: Qing Zhou

Förderung

  • Noncommunicable Chronic Diseases- National Science and Technology Major Project
  • The National Natural Science Foundation of China
  • MOE Changjiang Distinguished Professor Supporting Project
  • National Natural Science Foundation of China

Zitieren

APA

Wang, F., Wei, X. W., Yang, M. Y., Lu, C., Yang, X. R., Deng, J. Y., Chen, Z. H., & Zhou, Q. (2025). A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR ‐Mutant Non‐Small Cell Lung Cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70025

Vancouver

Wang F, Wei XW, Yang MY, Lu C, Yang XR, Deng JY, et al. A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR ‐Mutant Non‐Small Cell Lung Cancer. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70025

BibTeX
@article{Wang2025,
  author = {Wang, Fen and Wei, Xue-Wu and Yang, Ming-Yi and Lu, Chang and Yang, Xiao-Rong and Deng, Jia-Yi and Chen, Zhi-Hong and Zhou, Qing},
  title = {A Novel DNA Repair‐Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR ‐Mutant Non‐Small Cell Lung Cancer},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70025}
}
Kostenlos starten →